029 Group SE

Board/Management Information • May 10, 2005

News Details

Ad-hoc | 10 May 2005 07:31

Rhein Biotech N.V.: Changes in management and supervisory boards

Ad hoc announcement §15 WpHG Rhein Biotech N.V.: Changes in management and supervisory boards Rhein Biotech N.V.: Changes in management and supervisory boards Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Maastricht, May 10, 2005 Rhein Biotech N.V. announces that at the annual shareholders meeting of May 31, 2005 Mr. D. Ellens will resign as CEO and member of the management board and Mr. E. de la Houssaye and Mrs. A. van Broekhoven will resign as chairman and member of the supervisory board, respectively. At the annual meeting, Mr. D. Ellens will be proposed for appointment as the new chairman of the supervisory board and Mr. K. Moonen will be proposed as the new CEO and member of the management board. Mr. K. Moonen will also remain as the CEO of the company”s subsidiary Green Cross Vaccines Corporation in Korea. After the proposed changes, the supervisory board will consist of Messrs. D. Ellens and C. Hollenberg, and the management board will consist of Messrs. K. Moonen en P. Heijmans. Rhein Biotech N.V. Gaetano Martinolaan 95 6229 GS Maastricht Netherlands ISIN: NL0000230324 WKN: 919544 Listed: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart End of ad hoc announcement (c)DGAP 10.05.2005 Issuer’s information/explanatory remarks concerning this ad hoc announcement: Rhein Biotech is a member of the Berna Biotech Group, a leading player in vaccines. For further information Rhein Biotech N.V. Company Contact: Béatrice Keller Communication Manager E: communications@bernabiotech.com End of message (c)DGAP 100731 Mai 05